Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

24
Galectin Therapeutics IPF Patent Solidifies Platform Technology Status

2018-07-05 seekingalpha
Galectin Therapeutics (NASDAQ:GALT) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (NYSEARCA:IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise of a key departing officer continued to weigh on the price. Based on the recent Form 4 Filings, the selling pressure has abated because the officers have simply run out of options to sell.
TPIV FGEN GALTW GLPG GALTU LJPC GLPG KITE PFSCF GALT

8
2 Stable and 2 Speculative Biotech Stocks to Buy | InvestorPlace

2018-06-15 investorplace
Biotech stocks represent a peculiar conundrum. On one hand, they are scientifically the most exciting investment sector. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. But the industry is heavily marked with failures and agonizing disappointments.
ENTA GRFS SYRS LJPC

6
LJPC / La Jolla Pharmaceutical Co. 8-K (Current Report)

2018-05-14 sec.gov
Document UNITED STATES
LJPC

16
LJPC / La Jolla Pharmaceutical Co. 10-K/A (Annual Report)

2018-04-30 sec.gov
Document UNITED STATES
LJPC

2
LJPC / La Jolla Pharmaceutical Co. / BlackRock Inc. - null (Passive Investment)

2018-04-06 sec.gov
us5034596040_040518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) LA JOLLA PHARMACEUTICAL CO -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 503459604 -------------------------------------------------------- (CUSIP Number) March 31, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this
LJPC

2
LJPC / La Jolla Pharmaceutical Co. / BlackRock Inc. - null (Passive Investment)

2018-04-06 sec.gov
us5034596040_040518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) LA JOLLA PHARMACEUTICAL CO -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 503459604 -------------------------------------------------------- (CUSIP Number) March 31, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this
LJPC

2
LJPC / La Jolla Pharmaceutical Co. null

2018-03-27 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0X(# @;V)J#3P\+TQI;[email protected]$O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)[email protected] M8F#R A(,4X [email protected](&)[email protected],0G
LJPC

2
LJPC / La Jolla Pharmaceutical Co. FORM 8-K (Current Report)

2018-03-19 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
LJPC

2
LJPC / La Jolla Pharmaceutical Co. 424B5 (Prospectus)

2018-03-16 sec.gov
424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-221198 PROSPECTUS SUPPLEMENT (To Prospectus dated November 21, 2017)
LJPC

163
Your Daily Pharma Scoop: Abeona Update, Alexion Data, Solid Biosciences Setback

2018-03-16 seekingalpha
Today we will discuss Abeona Therapeutics (ABEO) after the company announced that it has nabbed a Rare Pediatric Disease designation from the FDA for ABO-202 for the treatment of CLN1 disease, which is a rare inherited disorder of the nervous system.
EXEL SLDB OVID ABEO AKCA SUPN BCRX TPIV ALXN JNJ IONS LJPC HAE ABEOW

2
LJPC / La Jolla Pharmaceutical Co. 424B5 (Prospectus)

2018-03-14 sec.gov
424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-221198 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell t
LJPC

Related Articles

ADAP: Adaptimmune Therapeutics Analysis and Research Report

8h - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

Silicon Investor Message Boards

This table lists all message boards related to LJPC / La Jolla Pharmaceutical Co. on message board site Silicon Investor.

La Jolla Pharmaceutical (LJPC)
CUSIP: 503459604